Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Updated
Inovio Pharmaceuticals, Inc is a biotechnology business based in the US. Inovio Pharmaceuticals shares (INO) are listed on the NASDAQ and all prices are listed in US Dollars. Inovio Pharmaceuticals employs 190 staff and has a trailing 12-month revenue of around USD$2.1 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced investors
Latest market close | USD$11.49 |
---|---|
52-week range | USD$5.13 - USD$33.79 |
50-day moving average | USD$12.103 |
200-day moving average | USD$11.755 |
Wall St. target price | USD$16.14 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.215 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.49 from 2021-02-25
1 week (2021-02-22) | N/A |
---|---|
1 month (2021-02-01) | N/A |
3 months (2020-12-01) | N/A |
6 months (2020-09-01) | N/A |
1 year (2020-03-01) | N/A |
---|---|
2 years (2019-03-01) | N/A |
3 years (2018-03-01) | N/A |
5 years (2016-03-01) | N/A |
Revenue TTM | USD$2.1 million |
---|---|
Gross profit TTM | USD$-82,005,389 |
Return on assets TTM | -26.14% |
Return on equity TTM | -100.68% |
Profit margin | 0% |
Book value | $1.933 |
Market capitalisation | USD$2 billion |
TTM: trailing 12 months
There are currently 43.1 million Inovio Pharmaceuticals shares held short by investors – that's known as Inovio Pharmaceuticals's "short interest". This figure is 0.5% down from 43.3 million last month.
There are a few different ways that this level of interest in shorting Inovio Pharmaceuticals shares can be evaluated.
Inovio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Inovio Pharmaceuticals shares currently shorted divided by the average quantity of Inovio Pharmaceuticals shares traded daily (recently around 22.6 million). Inovio Pharmaceuticals's SIR currently stands at 1.91. In other words for every 100,000 Inovio Pharmaceuticals shares traded daily on the market, roughly 1910 shares are currently held short.
However Inovio Pharmaceuticals's short interest can also be evaluated against the total number of Inovio Pharmaceuticals shares, or, against the total number of tradable Inovio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inovio Pharmaceuticals's short interest could be expressed as 0.21% of the outstanding shares (for every 100,000 Inovio Pharmaceuticals shares in existence, roughly 210 shares are currently held short) or 0.2142% of the tradable shares (for every 100,000 tradable Inovio Pharmaceuticals shares, roughly 214 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inovio Pharmaceuticals.
Find out more about how you can short Inovio Pharmaceuticals stock.
We're not expecting Inovio Pharmaceuticals to pay a dividend over the next 12 months.
Inovio Pharmaceuticals's shares were split on a 1:4 basis on 6 June 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inovio Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Inovio Pharmaceuticals shares which in turn could have impacted Inovio Pharmaceuticals's share price.
Over the last 12 months, Inovio Pharmaceuticals's shares have ranged in value from as little as $5.13 up to $33.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovio Pharmaceuticals's is 0.9963. This would suggest that Inovio Pharmaceuticals's shares are less volatile than average (for this exchange).
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.